A Randomised Parallel Group Double-Blind Phase II Study to Assess the Activity of TroVax (MVA-5T4) Versus Placebo in Patients With Relapsed Asymptomatic Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Trial Profile

A Randomised Parallel Group Double-Blind Phase II Study to Assess the Activity of TroVax (MVA-5T4) Versus Placebo in Patients With Relapsed Asymptomatic Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs MVA 5T4 (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms TRIOC
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 03 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top